The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients

Aino Latva‐Rasku, Miikka‐Juhani Honka, Joel Kullberg, +10

Diabetes Care

Insulin-stimulated glucose uptake in skeletal muscle, adipose tissue and liver: a positron emission tomography study

Miikka‐Juhani Honka, Aino Latva‐Rasku, Marco Bucci, +4

European Journal of Endocrinology

Insulin Resistance Is Associated With Enhanced Brain Glucose Uptake During Euglycemic Hyperinsulinemia: A Large-Scale PET Cohort

Eleni Rebelos, Marco Bucci, Tomi Karjalainen, +13

Diabetes Care

Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study

Jonas Oldgren, Sanna Laurila, Axel Åkerblom, +13

Diabetes Obesity and Metabolism

A Partial Loss-of-Function Variant in <i>AKT2</i> Is Associated With Reduced Insulin-Mediated Glucose Uptake in Multiple Insulin-Sensitive Tissues: A Genotype-Based Callback Positron Emission Tomography Study

Aino Latva‐Rasku, Miikka‐Juhani Honka, Alena Stančáková, +15

Diabetes

Both sedentary time and physical activity are associated with cardiometabolic health in overweight adults in a 1 month accelerometer measurement

Tanja Sjöros, Henri Vähä‐Ypyä, Saara Laine, +12

Scientific Reports

Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients—a description of the DAPACARD study

Axel Åkerblom, Jonas Oldgren, Aino Latva‐Rasku, +5

Upsala Journal of Medical Sciences

Insulin-stimulated brain glucose uptake correlates with brain metabolites in severe obesity: A combined neuroimaging study

Eleni Rebelos, Aino Latva‐Rasku, Kalle Koskensalo, +13

Journal of Cerebral Blood Flow & Metabolism